EBS

SEC source: 0001583098-26-000008 · wk-form4_1791402323.xml · nonDerivative · entry 1

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,921

F1 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on October 2, 2026.

F2 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001961994-26-000029 · wk-form4_1791206183.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,098

F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $6.52 to $6.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001961994-26-000024 · wk-form4_1783011439.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,098

F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001196632-26-000017 · wk-form4_1781118501.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,083

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001961994-26-000021 · wk-form4_1781118557.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,098

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001919170-26-000016 · wk-form4_1781118426.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,201

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001989644-26-000011 · wk-form4_1781118336.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,558

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · nonDerivative · entry 3

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,941

F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

F4 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · nonDerivative · entry 2

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,998

F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

F3 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001536908-26-000004 · wk-form4_1777930251.xml · nonDerivative · entry 3

Dayal Sujata Tyagi · CIK 0001536908 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,563

F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 8, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

F4 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.70 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001536908-26-000004 · wk-form4_1777930251.xml · nonDerivative · entry 2

Dayal Sujata Tyagi · CIK 0001536908 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,543

F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 8, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

F3 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.70 to $8.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · nonDerivative · entry 3

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,721

F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

F4 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · nonDerivative · entry 2

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,675

F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

F3 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · derivative · entry 4

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F5 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F6 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001685720-26-000003 · wk-form4_1777930077.xml · nonDerivative · entry 1

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,143

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001493692-26-000003 · wk-form4_1777930061.xml · derivative · entry 2

Fowler Neal Franklin · CIK 0001493692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001493692-26-000003 · wk-form4_1777930061.xml · nonDerivative · entry 1

Fowler Neal Franklin · CIK 0001493692 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,847

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001493324-26-000002 · wk-form4_1777930151.xml · derivative · entry 2

White Marvin L · CIK 0001493324 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001493324-26-000002 · wk-form4_1777930151.xml · nonDerivative · entry 1

White Marvin L · CIK 0001493324 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,839

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001190344-26-000012 · wk-form4_1777930137.xml · derivative · entry 2

FOWLER JOHN D JR · CIK 0001190344 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001190344-26-000012 · wk-form4_1777930137.xml · nonDerivative · entry 1

FOWLER JOHN D JR · CIK 0001190344 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,350

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001314596-26-000002 · wk-form4_1777930168.xml · derivative · entry 3

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F4 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F5 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001314596-26-000002 · wk-form4_1777930168.xml · nonDerivative · entry 2

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,294

F2 · shares: Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.

F3 · price: The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001314596-26-000002 · wk-form4_1777930168.xml · nonDerivative · entry 1

Katkin Keith · CIK 0001314596 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,775

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001536908-26-000004 · wk-form4_1777930251.xml · derivative · entry 4

Dayal Sujata Tyagi · CIK 0001536908 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F5 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F6 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001536908-26-000004 · wk-form4_1777930251.xml · nonDerivative · entry 1

Dayal Sujata Tyagi · CIK 0001536908 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,324

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · derivative · entry 4

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F5 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F6 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001583098-26-000004 · wk-form4_1777930221.xml · nonDerivative · entry 1

DeGolyer Donald W · CIK 0001583098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,202

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001380184-26-000005 · wk-form4_1777929828.xml · derivative · entry 2

Harsanyi Zsolt · CIK 0001380184 · Director · Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001380184-26-000005 · wk-form4_1777929828.xml · nonDerivative · entry 1

Harsanyi Zsolt · CIK 0001380184 · Director · Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,076

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0001380177-26-000004 · wk-form4_1777930129.xml · derivative · entry 2

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,296

Underlying: Common Stock · 11,296 shares

Expires 2033-04-30

F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.

F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

SEC source: 0001380177-26-000004 · wk-form4_1777930129.xml · nonDerivative · entry 1

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,761

F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

SEC source: 0002044279-26-000007 · wk-form4_1777667370.xml · nonDerivative · entry 1

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,914

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0002043716-26-000007 · wk-form4_1777667240.xml · nonDerivative · entry 1

Perl Jessica · CIK 0002043716 · SVP, General Counsel, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,286

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001242215-26-000012 · wk-form4_1777667176.xml · nonDerivative · entry 1

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 493,153

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001196632-26-000013 · wk-form4_1777667258.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 378,047

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001919170-26-000012 · wk-form4_1777667327.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,219

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001961994-26-000017 · wk-form4_1777667409.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,792

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001989644-26-000007 · wk-form4_1777667211.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,299

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001961994-26-000013 · wk-form4_1775246752.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,681

F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0002044279-26-000003 · wk-form4_1772763692.xml · nonDerivative · entry 1

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,803

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0002043716-26-000005 · wk-form4_1772763573.xml · nonDerivative · entry 1

Perl Jessica · CIK 0002043716 · SVP, General Counsel, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,004

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001242215-26-000008 · wk-form4_1772764826.xml · nonDerivative · entry 1

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,445

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of performance stock units.

SEC source: 0001196632-26-000009 · wk-form4_1772762821.xml · nonDerivative · entry 1

LINDAHL RICHARD S · CIK 0001196632 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,367

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001989644-26-000005 · wk-form4_1772763598.xml · nonDerivative · entry 1

Hartzel William · CIK 0001989644 · SVP, Bioservices

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,188

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001961994-26-000009 · wk-form4_1772762934.xml · nonDerivative · entry 1

Williams Paul Anthony · CIK 0001961994 · SVP, Products Business

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,681

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001919170-26-000009 · wk-form4_1772762761.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,108

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0002044279-26-000003 · wk-form4_1772763692.xml · derivative · entry 2

Lowry Simon C · CIK 0002044279 · SVP, R&D, CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,833

Underlying: Common Stock · 44,834 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0002043716-26-000005 · wk-form4_1772763573.xml · derivative · entry 2

Perl Jessica · CIK 0002043716 · SVP, General Counsel, Corp Sec

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,647

Underlying: Common Stock · 46,702 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001242215-26-000008 · wk-form4_1772764826.xml · derivative · entry 2

PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,784,694

Underlying: Common Stock · 252,194 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.